NEW YORK (GenomeWeb News) – Adaptive Biotechnologies today announced the signing of a collaborative agreement with Bristol-Myers Squibb for the use of Adaptive's technology to discover immunological biomarkers in cancer.

Seattle-based Adaptive Bio will use its immune profiling assay called immunoSeq to identify biomarkers that may be informative about drug response. The next-generation sequencing-based assay characterizes the repertoire of T and B cell receptors.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The ancestors of the Arizona bark scorpion and other scorpions and spiders underwent whole-genome duplication, KJZZ reports.

A cryptographic approach could help researchers keep genomic data private while researchers analyze it, Scientific American reports.

Andy Page, the former president of 23andMe, has joined a diabetes-management startup, according to CNBC.

In Cell this week: regulatory changes in pancreatic cancer, metabolic shifts in Alzheimer's disease, and more.